Axovant Gene Therapies Ltd (NASDAQ:AXGT) – Investment analysts at Svb Leerink cut their Q4 2020 earnings estimates for Axovant Gene Therapies in a research report issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar now expects that the company will post earnings per share of ($0.62) for the quarter, down from their previous forecast of ($0.61). Svb Leerink also issued estimates for Axovant Gene Therapies’ Q2 2021 earnings at ($0.70) EPS, FY2021 earnings at ($2.68) EPS, FY2022 earnings at ($2.54) EPS and FY2023 earnings at ($2.76) EPS.
Axovant Gene Therapies (NASDAQ:AXGT) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.54.
NASDAQ AXGT opened at $4.88 on Monday. The company has a market capitalization of $114.64 million, a price-to-earnings ratio of -0.61 and a beta of 1.19. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.41 and a quick ratio of 1.41. Axovant Gene Therapies has a 12 month low of $3.81 and a 12 month high of $19.60. The company’s fifty day moving average price is $5.60 and its two-hundred day moving average price is $6.34.
Hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Axovant Gene Therapies by 955.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock worth $27,000 after acquiring an additional 3,821 shares during the period. Barclays PLC acquired a new position in Axovant Gene Therapies in the third quarter valued at approximately $65,000. Jane Street Group LLC boosted its stake in Axovant Gene Therapies by 28.8% in the second quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock valued at $289,000 after acquiring an additional 10,375 shares during the period. Finally, BlackRock Inc. bought a new position in shares of Axovant Gene Therapies during the second quarter valued at approximately $1,482,000. 14.80% of the stock is currently owned by institutional investors and hedge funds.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Story: Insider Trading – What You Need to Know
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.